The involvement of rare cancer patients in clinical research

Use of genetic variance to identify potential therapeutic targets

Introduction of PET tracers to the WINTHER trial

Application of next generation sequencing

Next generation sequencing and WIN therapeutics

Identifying targets with systems medicine

Importance of early detection and the ‘Beyond the Shock’ programme

Shortening the timeline for clinical drug developments

Building international collaborations and the WINTHER trial

New drugs on the CML horizon; choosing the correct therapies

The evolving landscape in the management of CML

Maintenance therapy in multiple myeloma; the way forward